Safety and tolerability of antiepileptic drug treatment in children with epilepsy

Drug Safety

Volumn 35, Issue 7, 2012, Pages 519-533

  Guerrini, Renzo ^a   Zaccara, Gaetano ^b   La Marca, Giancarlo ^a   Rosati, Anna ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAN GIOVANNI DI DIO HOSPITAL   (Italy)

Author keywords

Adverse drug reactions; Antiepileptic drugs; Carbamazepine; Children; Epilepsy; Eslicarbazepine acetate; Felbamate; Gabapentin; Lacosamide; Lamotrigine; Levetiracetam; Oxcarbazepine; Phenobarbital; Phenytoin; Pregabalin; Primidone; Rufinamide; Stiripentol; Tiagabine; Topiramate; Vigabatrin; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; NITRAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABDOMINAL PAIN; ABSENCE; AGRANULOCYTOSIS; ANHIDROSIS; ANOREXIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; APHASIA; APLASTIC ANEMIA; ASPIRATION; ASPIRATION PNEUMONIA; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; BLURRED VISION; BRAIN DISEASE; CHOREOATHETOSIS; CONCENTRATION LOSS; CONSTIPATION; DEPRESSION; DIARRHEA; DIPLOPIA; DISEASE CONTROL; DISEASE COURSE; DISEASE PREDISPOSITION; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSKINESIA; EPILEPSY; EPILEPTIC STATE; EYE MOVEMENT DISORDER; FEVER; FOCAL EPILEPSY; GENETIC ASSOCIATION; GRAND MAL SEIZURE; HALLUCINATION; HEADACHE; HEMATOLOGIC DISEASE; HOSTILITY; HUMAN; HYPERSALIVATION; INFANTILE SPASM; INFECTION; INSOMNIA; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; LYMPHOMA; MEGALOBLASTIC ANEMIA; MYOCLONUS; MYOCLONUS EPILEPSY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PARESTHESIA; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RASH; RESPIRATION DEPRESSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SYMPTOMATIC EPILEPSY; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TIC; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT RESPONSE; TREMOR; URINE INCONTINENCE; UROLITHIASIS; VISUAL FIELD DEFECT; VOMITING; WEIGHT GAIN;

AGE FACTORS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; HUMANS; INFANT; RISK FACTORS;

EID: 84862582703     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11630700-000000000-00000     Document Type: Review

References (133)

1. Clarkson A, Chaoonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462-7 (Pubitemid 35440692)
2. Connock M, Frew E, Evans BW, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review. Health Technol Assess 2006; 10: iii, ix-118
3. Chu-Store C, Thiele EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol 2010; 17: 214-23
4. Johann-Liang R, Pharm JW, Chen M, et al. Pediatric drug surveillance and the food and drug administration's adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol Drug Saf 2009; 18: 24-7
5. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007; 161: 282-90 (Pubitemid 46364332)
6. Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2009; 22: 739-60
7. Gillham R, Baker G, Thompson R, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatment. Epilepsy Res 1996; 24: 47-55 (Pubitemid 26191611)
8. Guerrini R, Belmonte A, Genton P. Antiepileptic druginduced worsening of seizures in children. Epilepsia 1998; 39 Suppl. 3: S2-10 (Pubitemid 28215208)
9. Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs.DevMed Child Neurol 2006; 48: 394-8
10. Parmeggiani L, Seri S, Bonanni P, et al. Electrophysiological characterization of spontaneous and carbamazepineinduced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. Clin Neurophysiol 2004; 115: 50-8 (Pubitemid 38045594)
11. Asconape J, Diedrich A, Della Badia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000; 41: 479-81 (Pubitemid 30196616)
12. Lortie A, Chiron C, Mumford J, et al. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993; 43 Suppl. 5: S24-7
13. Guerrini R, Belmonte A, Parmeggiani L, et al. Myoclonic status epilepticus following high dose lamotrigine therapy. Brain Dev 1999; 21: 420-4 (Pubitemid 29371853)
14. Cerminara C, Montanaro ML, Curatolo P, et al. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology 2004; 63: 373-5 (Pubitemid 38971149)
15. Chapman K, Holland K, Erenberg G. Seizure exacerbation associated with oxcarbazepine in idiopathic focal epilepsy of childhood. Neurology 2003; 61: 1012-3 (Pubitemid 37248670)
16. Gelisse P, Genton P, Kuate C, et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282-6 (Pubitemid 39350341)
17. Kaddurah AK, Holmes GL. Possible precipitation of myoclonic seizures with oxcarbazepine. Epilepsy Behav 2006; 8: 289-93 (Pubitemid 43103862)
18. Skardoutsou A, Voudris KA, Vagiakou EA. Nonconvulsive status epilepticus associated with tiagabine therapy in children. Seizure 2003; 12: 599-601 (Pubitemid 37509057)
19. Ferrendelli JA. Concern with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 2001; 42 Suppl 4: 28-30 (Pubitemid 32802084)
20. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061-75 (Pubitemid 44631387)
21. Krasowski M. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals 2010; 3: 1909-35
22. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-76 (Pubitemid 351991390)
23. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347-56 (Pubitemid 38352562)
24. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second-and third-generation antiepileptic drugs. Expert Rev Neurother 2010; 10: 119-40
25. Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-7 (Pubitemid 28074354)
26. Novy J, Patsalos PN, Sander JW, et al. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011; 20: 20-3
27. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41: 961-4
28. Camfield P, Camfield C. Monitoring for adverse effects of antiepileptic drugs. Epilepsia 2006; 47 Suppl. 1: 31-4 (Pubitemid 44527132)
29. Bourgeois BF. Determining the effects of antiepileptic drugs on cognitive function in pediatric patients with epilepsy. J Child Neurol 2004; Suppl 1: 15-24
30. Korn-Merker E, Borusiak P, Boenigk HE. Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res 2000; 39: 27-32
31. Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicenter, open-label study. Dev Med Child Neurol 2001; 43: 269-73 (Pubitemid 32328203)
32. Levisohn PM, Mintz M, Hunter SJ, et al. Neurocognitive effects of adjunctive levetiracetam in children with partialonset seizures: a randomized, double-blind, placebocontrolled, noninferiority trial. Epilepsia 2009; 50: 2377-89
33. Martinez W, Ingenito A, Blakeslee M, et al. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy Behav 2006; 9: 448-56 (Pubitemid 44615634)
34. Wier HA, Cerna A, So TY. Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. Paediatr Drugs 2011; 13 (2): 97-106
35. Uldall P, Bulteau C, Pedersen SA, et al. Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res 2000; 42: 159-68
36. Rosenfeld WE, Doose DR, Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999; 20: 339-44 (Pubitemid 29250178)
37. Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005; 112: 214-22 (Pubitemid 41337067)
38. Kluger G, Zsoter A, Holthausen H. Long-term of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol 2008; 12: 19-23 (Pubitemid 350258688)
39. Grosso S, Cordelli DM, Coppola G, et al. Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. Eur J Neurol 2008; 15: 940-6
40. Gavatha M, Ioannou I, Papavasiliou SA. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2001; 20: 691-3
41. Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999; 40: 1618-26 (Pubitemid 29518093)
42. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebocontrolled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356 (9242): 1638-42
43. Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia 2009; 50: 2362-8
44. Bourgeois BF, D'Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav 2005; 7: 375-82 (Pubitemid 41614131)
45. Northam RS, Hernandes AW, Litzinger MJ, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 2005; 33: 337-44 (Pubitemid 41501553)
46. Jan MM, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol 2009; 40: 347-50
47. Wheless JW, Conry J,KraussG, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24: 1520-5
48. Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol 2010; 43: 155-8
49. Cho YJ, Heo K, Kim WJ, et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 2009; 50: 1910-9
50. Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009; 13: 3-9
51. Dalla Bernardina B, Fontana E, Vigevano F, et al. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia 1995; 36: 687-91
52. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 2000; 9: 137-41 (Pubitemid 30209804)
53. Guilhoto LM, Loddenkemper T, Gooty VD, et al. Experience with lacosamide in a series of children with drugresistant focal epilepsy. Pediatr Neurol 2001; 55: 414-9
54. Gross-Tsur V, Shalev RS. Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 2004; 62: 299-300 (Pubitemid 38167145)
55. Gay PE, Mechman GF, Coskey JS, et al. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Psychol Rep 1995; 77: 1208-10
56. Mikati MA, Choueri R, Khurana DS, et al. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 1998; 42 Suppl 1: 57-62
57. Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurol Scand 1996; 93: 1-8 (Pubitemid 26033948)
58. Verrotti A, D'Adamo E, Parisi P, et al. Levetiracetam in childhood epilepsy. Paediatr Drugs 2010; 12: 177-86
59. Das KB, Harris C, Smyth DP, et al. Unusual side effects of lamotrigine therapy. J Child Neurol 2003; 18: 479-80 (Pubitemid 37038552)
60. Piñ a-Garza JE, Elterman RD, Ayala R, et al. Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old. J Child Neurol 2008; 23: 853-61
61. Sackellares JC, Krauss G, Sommerville KW, et al. Occurrence of psychosis in patients in patients with epilepsy randomzed to tiagabine or placebo treatment. Epilepsia 2002; 43: 394-8 (Pubitemid 34297177)
62. Messnheimer J. Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol 2002; 17 Suppl 2: 34-42
63. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49: 108-16
64. Kerrick JM, Kelly BJ, Maister BH, et al. Involuntary movement disorders associated with felbamate. Neurology 1995; 45: 185-7
65. Zesiewicz TA, Sullivan KL, Hauser RA. Chorea induced by lamotrigine [letter]. J Child Neurol 2006; 21: 357
66. Sotero De Menezes MA, Rho JM, Murphy P, et al. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia 2000; 41: 862-7 (Pubitemid 30439578)
67. Gijsen VM, de Wildt SN, Ito S. Probability of rash related to gabapentin therapy in a child. Ann Pharmacother 2009; 43: 387-9
68. Dooley J, Camfield P, Gordon K, et al. Lamotrigineinduced rash in children. Neurology 1996; 46: 240-2
69. Kim SC, Seol IJ, Kim SJ. Hypohidrosis-related symptoms in pediatric epileptic patients with topiramate. Pediatr Int 2010; 52: 109-12
70. Sparagana SP, Strand WR, Adams RC. Felbamate urolithiasis. Epilepsia 2001; 42: 682-5 (Pubitemid 32453654)
71. Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67 Suppl. 4: 28-33
72. Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009; 50: 184-94
73. Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50: 195-205
74. Thelle T, Gammelgaard L, Hansen JK, et al. Reversible magnetic resonance imaging and spectroscopy abnormalities in the course of vigabatrin treatment for West syndrome. Eur J Paediatr Neurol 2011; 15: 260-4
75. Beran RG, Berkovic S, Buchanan N, et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996; 5: 259-65 (Pubitemid 26405379)
76. Sachdeo R, Narang-Sachdeo SK, Shumaker RC, et al. Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy. Epilepsia 1997; 38: 887-92 (Pubitemid 27323597)
77. Paul E, Conont KD, Dunne IE, et al. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. Epilepsy Res 2010; 90: 151-6
78. Albsoul-Younes AM, Lasem Ha, Ajlouni SF, et al. Topiramate slow titration: improved efficacy and tolerability. Pediatr Neurol 2004; 31: 349-52 (Pubitemid 39424201)
79. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33: 1037-42 (Pubitemid 29489983)
80. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48: 1223-44 (Pubitemid 47063067)
81. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolites formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3: 367-77 (Pubitemid 34778003)
82. Sadeque AJM, Fisher MB, Korzekwa KR, et al. Human CYP2C9 mediate formation of the hepatotoxin 4-enevalproic acid. J Pharmacol Exp Ther 1997; 283: 698-703 (Pubitemid 27514629)
83. Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003; 192: 37-48 (Pubitemid 37153342)
84. Walgren JL, Mitchell MD, Thomson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35: 325-61 (Pubitemid 40691298)
85. ParkBK, PirmohamedM, KitteringhamNR.The role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. Chem Res Toxicol 1998; 11: 969-88 (Pubitemid 28447286)
86. Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987; 36: 581-90 (Pubitemid 17026072)
87. Uetrecht J. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxicol 1999; 12: 387-95 (Pubitemid 29352401)
88. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5 (Pubitemid 34303674)
89. Guengerich FP. Cytochrome P450 and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8 (1): E101-11
90. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43 Suppl. 3: 53-9 (Pubitemid 34633697)
91. Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9: 1225-9 (Pubitemid 26403826)
92. Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem Res Toxicol 1997; 10: 457-62 (Pubitemid 27176309)
93. Kapetanovic IM, Torchin CD, Strong JM, et al. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact 2002; 142: 119-34 (Pubitemid 35238045)
94. Dieckhaus CM, Roller SG, Santos WL, et al. Role of glutathione S-transferases A1-1, M1-1, and P1-1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite. Chem Res Toxicol 2001; 14: 511-6 (Pubitemid 32480018)
95. Popovic M, Nierkens S, Pieters R, et al. Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chem Res Toxicol 2004; 17: 1568-76 (Pubitemid 39665547)
96. PellockJM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res 2006; 71: 89-101 (Pubitemid 44416200)
97. Zaccara G, Cincotta M, Borgheresi A, et al. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord 2004; 6: 153-68 (Pubitemid 39480678)
98. Masmoudi K, Gras-Champel V, Masson H, et al. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006; 39: 9-12 (Pubitemid 43235443)
99. Guerrini R, Belmonte A, Canapicchi R, et al. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998; 39: 27-32 (Pubitemid 28116838)
100. Edwards SG, Hubbard V, Aylett S, et al. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med 1999; 75: 680-1 (Pubitemid 29495605)
101. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro risk assessment. J Clin Invest 1988; 82: 1826-32 (Pubitemid 19054926)
102. Ferrell Jr PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9 (10): 1543-6
103. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486
104. Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987; 28: S23-9 (Pubitemid 18035484)
105. Perucca E. Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45: 351-63
106. Stewart JD, Horvath R, Baruffini E, et al. Polymerase g gene POLG determines the risk of sodium valproateinduced liver toxicity. Hepatology 2010; 52: 1791-6
107. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities: II. US experience since 1984. Neurology 1989; 139: 201-7 (Pubitemid 19059304)
108. Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008; 71: 1527-34
109. Peyrière H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155: 422-8 (Pubitemid 44050579)
110. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353: 2190-4 (Pubitemid 29295251)
111. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-5 (Pubitemid 17119309)
112. Binaghi M, Koso M, Saiag P, et al. Ocular involvement in Lyell's syndrome: incidence, evolution, prognosis. Ophtalmologie 1988; 2: 121-2
113. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study fromWestGermany.ArchDermatol 1991; 127: 839-42
114. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85 (Pubitemid 24333193)
115. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6 (Pubitemid 23029676)
116. Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265-9 (Pubitemid 28007514)
117. Blackbum SC, Oliart D, Garcia RL, et al. Antiepileptic and blood dyscrasia; a cohort study. Pharmacotherapy 1998; 18: 1277-83
118. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38 Suppl. 2: S44-8 (Pubitemid 38328164)
119. Binek J, Hany A, Heer M. Valproic acid-induced pancreatitis: report of a case and review of literature. J Clin Gastroenterol 1991; 13: 690-3
120. Zaccara G, Campostrini R, Paganini M, et al. Acute changes of blood ammonia may predict short-term effects of valproic acid. Neurology 1984; 34: 1519-21 (Pubitemid 14024301)
121. Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 1993; 8: 19-27 (Pubitemid 23039225)
122. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate, associated, acute, secondary angle-closure glaucoma. Ophthalmology 2004; 111: 109-11 (Pubitemid 38032217)
123. Watanabe T, Yoshikawa H, Yamazaki S, et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 2005; 20: 814-7 (Pubitemid 40663170)
124. Guerrini R. Epilepsy in children. Lancet 2006; 367: 499-524 (Pubitemid 43208906)
125. Sulzbacher S, Farwell JR, Temkin N, et al. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr 1999; 38: 387-94 (Pubitemid 29328298)
126. Donati F, Gobbi G, Campistol J, et al. The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure 2007; 16: 670-9 (Pubitemid 350027187)
127. Kang HC, Eun BL, Wu LC, et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia 2007; 48: 1716-23
128. Bootsma HP, Aldenkamp AP, Diepman L, et al. The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia 2006; 47 Suppl. 2: 24-7 (Pubitemid 44684615)
129. Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611-3 (Pubitemid 34020103)
130. Best JL, Acheson JF. The natural history of vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2005; 19: 41-4 (Pubitemid 40192637)
131. Kraemer G, Ried S, Landau K, et al. Vigabatrin: reversibility of severe concentric visual field defects after early detection and drug withdrawal. A case report. Epilepsia 2000; 41 Suppl.: 144
132. Guideline for prescribing vigabatrin in children has been revised. Vigabatrin Paediatric Advisory Group. BMJ 2000; 320 (7246): 1404-5
133. Nousiainen I, Mantyjarvi M, Kälviäinen R. No reversion in vigabatrin-associated field defects.Neurology 2001; 57: 1916-7